+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic value of blood levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in advanced non-small cell lung cancer (NSCLC) patients



Prognostic value of blood levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in advanced non-small cell lung cancer (NSCLC) patients



Journal of Clinical Oncology 24(18_Suppl): 7196-7196



NlmCategory="UNASSIGNED">7196 Background: VEGF and bFGF are among the most important angiogenic factors. We have explored these angiogenesis mediators in plasma and its prognostic significance in advanced NSCLC. Were enrolled 451 patients with advanced NSCLC, stages IIIB and IV and treated with cisplatin and docetaxel. Blood was collected before chemotherapy. Plasma VEGF and bFGF levels were assessed by commercial ELISA (sensitivity 5 pg/ml). In parallel plasma from 32 age and gender-matched controls was used. Median age was 61 years (35-82) and 84% were males. 99% had performance status 0-1. 84% were in stage IV and 16% in stage IIIB. The histological subtypes were: 32% squamous cell carcinoma, 50% adenocarcinoma, 14% anaplastic large cell, and 4% undifferentiated. 41% of the patients received second line chemotherapy. 1% achieved complete response (CR), 36% partial response (PR), 35% had stable disease (SD) and 28% progressive disease (PD). Patient's median plasma levels of VEGF (20 pg/ml, [6-203]) differ significantly (p = 0.04) from controls (14 pg/ml, [7-53]), but in contrast bFGF levels were not different, 14 pg/ml [5-960] vs 10 pg/ml [6-278] respectively. There were not differences in patients according to histology, site of metastasis and ECOG; however we could observe a tendency with stage for both factors: bFGF 9 pg/ml [5-24] in stage IIIB vs 15 pg/ml [6-960], p = 0.071 and VEGF 17 pg/ml [6-145] in IIIB vs 21 pg/ml [6-203] in IV, p = 0.086. It could not be observed any differences in response to therapy for both angiogenic factors; CR+PR patients presented median VEGF of 18 pg/ml [6-71] and bFGF 11 pg/ml [6-960] vs 20 pg/ml of VEGF [6-203] and 15 pg/ml of bFGF [5-395] in the SD+PD group. In the multivariate analysis we could not find that VEGF and bFGF plasma levels were predictors for time to progression (TTP) and overall survival (OS). VEGF but not bFGF levels in patients are significantly higher in patients than in controls. In our cohort of patients with advanced NSCLC we have not found any relationship between serum VEGF and bFGF levels with stage, histology, response, site of metastasis, TTP and OS. No significant financial relationships to disclose.

(PDF emailed within 1 workday: $29.90)

Accession: 058637640

Download citation: RISBibTeXText

PMID: 27953725


Related references

Determination of the prognostic value blood levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in advanced non-small cell lung cancer (NSCLC) patients. 2007

Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. European Journal of Cardio-Thoracic Surgery 25(3): 443-448, 2004

Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. European Journal of Haematology 66(2): 83-88, 2001

Vascular endothelial growth factor and basic fibroblast growth factor levels change after chemotherapy in non-small cell lung cancer patients Correlation with tumor response, number of platelets, and leucocytes. Proceedings of the American Association for Cancer Research Annual Meeting 43: 894, 2002

Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment. Vnitrni Lekarstvi 53(11): 1171-1176, 2008

Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer 50(1): 51-58, 2005

Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression in superficial transitional cell bladder carcinoma. Ai Zheng 22(3): 307-309, 2003

Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Research 18(2a): 1123-1127, 1998

Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery. Breast Cancer Research and Treatment 93(1): 35-40, 2005

Comparison of invasion by human microvascular endothelial cell lines in response to vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in a threedimensional (3D) cell culture system. Malaysian Journal of Pathology 37(3): 219-225, 2016

Basic fibroblast growth factor and vascular endothelial growth factor measured in sera from patients with non-small cell lung cancer. Tumor Biology 18(SUPPL 2): 13, Sept, 1997

Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinoma. Anticancer Research 21(2b): 1423-1429, 2001

Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia. British Journal of Haematology 113(2): 400-406, 2001

Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology 3(3): 314-316, 2008

Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study. Clinical Cancer Research 14(5): 1407-1412, 2008